Identification of microRNAs as potential biomarkers for lung adenocarcinoma using integrating genomics analysis

Abstract

Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer, but novel biomarkers for early diagnosis are lacking. Extensive effort has been exerted to identify miRNA biomarkers in LUAD. Unfortunately, high inter-lab variability and small sample sizes have produced inconsistent conclusions in this field. To resolve the above-mentioned limitations, we performed a comprehensive analysis based on LUAD miRNome profiling studies using the robust rank aggregation (RRA) method. Moreover, miRNA-gene interaction network, pathway enrichment analysis and Kaplan-Meier survival curves were used to investigate the clinical values and biological functions of the identified miRNAs. A total of six common differentially expressed miRNAs (DEMs) were identified in LUAD. An independent cohort further confirmed that four miRNAs (miR-21-5p, miR-210-3p, miR-182-5p and miR-183-5p) were up-regulated and two miRNAs (miR-126-3p and miR-218-5p) were down-regulated in LUAD tissues. Pathway enrichment analysis also suggested that the above-listed six DEMs may affect LUAD progression via the estrogen signaling pathway. Survival analysis based on the TCGA dataset revealed the potential prognostic values of six DEMs in patients with LUAD (P-value<0.01). In conclusion, we identified a panel of six miRNAs from LUAD using miRNome profiling studies. Our results provide evidence for the use of these six DEMs as novel diagnostic and prognostic biomarkers for LUAD patients.

miR-190, CDK1, MCM10 and NDC80 predict the prognosis of the patients with lung cancer

“…By targeting integrin, beta 1 (ITGB1), miR-493-5p plays a prognostic role in NSCLC and could be used to diagnose the disease (28). Four upregulated miRNAs and two downregulated miR- NAs (including miR-218-5p) were identified in lung adenocarcinoma (LUAD) tissues and may represent promising diagnostic and prognostic markers for patients with LUAD (29). Overexpression of miR-200c plays an oncogenic role in NSCLC and correlates markedly with adverse prognosis; thus, it may serve as a prognostic biomarker for patients with NS-CLC (30).…”

Diagnostic Value of Plasma MicroRNAs for Lung Cancer Using Support Vector Machine Model

“…The ten miRNAs explored in the present study have been evaluated as lung cancer markers in other studies. Potential mechanisms of the miRNAs on lung cancer were explored in previous study (Seen in Table 7), the main signaling pathways including PI3K/Akt/NF-Κb (miR-21, miR-223, miR-145, miR-126, and miR-30a) [24][25][26][27][28] , STAT3 (miR-126, and miR-197) [27,29,30] , estrogen (miR-21 and miR-210) [31] , et al Table 7. Potential mechanisms of the miRNAs on lung cancer miRNAs Pathways miR-20a angiogenesis, TGF-β pathway, platelet-derived growth factor pathway, and oxidative stress response [32] miR-21 PI3K/AKT/NF-κB signaling pathway, and estrogen signaling pathway [24] ; autophagy-related AMPK/ULK1 signaling pathway [56] miR-210 estrogen signaling pathway [31] miR-223 Notch/miR-223/FBXW7 pathway [57] ; NF-κB signaling pathway [58] ;…”

Spatial Transcriptomics Inferred from Pathology Whole-Slide Images Links Tumor Heterogeneity to Survival in Breast and Lung Cancer

“…Others have also associated miR-17 [42,43,44] and miR-29 [45,46] with breast cancer. miR-17 was also chosen for lung since the miR-17 family was shown to be universally over-expressed in many cancers, including lung [32], and has been directly associated with lung cancer [47,48,49] as has miR-21 [50,51].…”